Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 456 participants.
Also called NCT04707768
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 456 participants
- Sponsor
- Registry
-
NCT04707768
-
- Other papers using this trial's data
- Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04707768. Randomized; no masking; primary purpose treatment. Start 2021-06-18 (actual); primary completion 2023-01-06 (actual). Results posted on 2025-01-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
- Condition
- Anemia Associated With Chronic Kidney Disease (CKD (chronic kidney disease))
- Intervention (Drug)
- Vadadustat
- Intervention (Drug)
- Mircera®
- Lead sponsor
- Akebia Therapeutics
Record details
- Record id
cardio:ct-nct04707768- Content hash
ad569a236c80d6b482c5a7135f878371d523aeb844f80a37fa5a1f5cb297f229